Jayme Aschemeyer
Endocrinology, Diabetes & Metabolism · Southfield, MINPI 1548581861
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (38.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Dexcom, Inc. accounts for 62.8% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $4,806 and has fallen 93.7% since, to $302 in 2025.
Across 159 payments — averaging $77.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$8K
- Medtronic$3K
- Novo Nordisk$431
- Lilly USA, LLC$269
- Xeris Pharmaceuticals, Inc.$179
- Amgen$138
- plus $607 from 17 others
What the payments were for
- Speaking & faculty fees$4,00032%
- Travel & lodging$4,81839%
- Food & beverage$3,50228%
- Education$671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 15 | $7,773 |
| Medtronic(2 entities) | 49 | $2,989 |
| Novo Nordisk | 27 | $431 |
| Lilly USA, LLC | 19 | $269 |
| Xeris Pharmaceuticals, Inc. | 9 | $179 |
| Amgen(2 entities) | 3 | $138 |
| Shire North American Group Inc | 8 | $130 |
| AstraZeneca(2 entities) | 6 | $89 |
| Radius Health, Inc. | 3 | $86 |
| Merck | 5 | $65 |
| AbbVie | 2 | $32 |
| EUSA Pharma (US) LLC | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Valeritas, Inc. | 2 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Alvogen Inc | 1 | $14 |
| BD | 1 | $14 |
| Lifescan, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Novartis | 1 | $12 |
| Mannkind Corporation | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM CGM$3,794
- DEXCOM G6 CGM SYSTEM$3,746
- MINIMED 770G$873
- MINIMED 780G$867
- RYBELSUS$125
- MOUNJARO$125
- TEPEZZA$110
- Ozempic$107
- INPEN SMART INSULIN DELIVERY SYSTEM$101
How this compares
$12,387 in reported general payments places this provider in the 80th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 271 | $478,578 |
| TrulicityDulaglutide | 225 | $381,130 |
| JardianceEmpagliflozin | 193 | $235,995 |
| MounjaroTirzepatide | 115 | $195,453 |
| JanuviaSitagliptin Phosphate | 43 | $66,231 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $59,195 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 233 | $48,587 |
| FarxigaDapagliflozin Propanediol | 39 | $46,639 |
| HumatropeSomatropin | 13 | $37,202 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $35,634 |
| Humalog Kwikpen U-100Insulin Lispro | 64 | $33,944 |
| Novolog FlexpenInsulin Aspart | 92 | $32,457 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $32,280 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $26,760 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $23,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humatrope, Humalog | $269 | $621,243372 claims |
| Novo NordiskOzempic, Novolog | $431 | $492,491307 claims |
| Boehringer IngelheimJardiance | $22 | $235,995193 claims |
| MerckJanuvia | $65 | $66,23143 claims |
| AstraZenecaFarxiga | $89 | $46,63939 claims |
| AbbVieSynthroid | $32 | $4,53135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Southfield
- Kirit ToliaSouthfield$29K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.